Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 4D Molecular Therapeutics Inc (NQ: FDMT ) 17.94 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 23 Open 17.94 Bid (Size) 17.20 (1) Ask (Size) 17.93 (1) Prev. Close 17.94 Today's Range 17.94 - 17.94 52wk Range 9.440 - 36.25 Shares Outstanding 42,052,980 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 21, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session July 18, 2024 Via Benzinga Performance YTD -15.58% -15.58% 1 Month -22.84% -22.84% 3 Month -26.02% -26.02% 6 Month -3.29% -3.29% 1 Year -0.39% -0.39% More News Read More Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights July 18, 2024 Via Benzinga Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts June 26, 2024 Via Benzinga Analyst Expectations For 4D Molecular Therapeutics's Future June 07, 2024 Via Benzinga FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm July 17, 2024 From The Schall Law Firm Via Business Wire 4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate July 17, 2024 Via Benzinga 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity July 17, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 17, 2024 Via Benzinga 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy June 24, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast June 18, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting June 08, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside June 07, 2024 Via Benzinga Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 06, 2024 Via Benzinga Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released June 06, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session June 06, 2024 Via Benzinga 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference June 06, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting June 04, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences June 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference May 30, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights May 09, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conference May 07, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces Presentations at ARVO 2024 Annual Meeting May 01, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation April 18, 2024 Via Benzinga Topics ETFs Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
